CliffBio
small molecule

VIZIMPRO

DACOMITINIB

Loss of exclusivitySeptember 2032latest FDA-listed patent expiry
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameVIZIMPRO
Active ingredientDACOMITINIB
Strength30MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2018
Marketing statusRX

Listed patents

PatentExpiresType
7772243September 2032substance, product
10603314February 2026use U-3337
10596162February 2026use U-3338

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIZIMPRO patent cliff — loss of exclusivity September 2032 | CliffBio